12 | MD Anderson Cancer Center

December 13, 2023

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...

December 12, 2023

ABSTRACT: LBA-2

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS)...

December 10, 2023

ABSTRACT: 620 Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing...

December 06, 2023

ABSTRACTS: 162, 309, 322, 364, 741, 774, 856, 983 SAN DIEGO ― The University of Texas MD Anderson Cancer Center’s Research Highlights...

Newsroom